瓦尔贝纳治疗晚期动症:一个系统性审查和网络元分析
Taro Kishi1, Kenji Sakuma, Nakao Iwata
1Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.
International clinical psychopharmacology
|September 11, 2023
概括
与40毫克/天相比,80毫克/天的瓦尔贝纳 (VAL) 对晚期运动障碍 (TD) 的疗效有所改善,安全性和耐受性相似. 建议增加剂量,如果较低剂量耐受良好,但反应不足.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 迟性运动障碍 (TD) 是一种超运动运动障碍.
- 瓦尔贝纳是一种已批准的TD治疗方法.
- 需要进一步澄清在TD中对瓦尔贝纳的最佳剂量.
研究的目的:
- 在TD患者中,系统地比较两种瓦尔贝纳剂量 (40 mg/天和80 mg/天) 的疗效,可接受性,耐受性和安全性.
- 阐明瓦尔贝纳对TD治疗结果的剂量依赖性影响.
主要方法:
- 一个系统的审查和频率网络的元分析.
- 瓦尔贝纳80毫克/天 (VAL80) 和瓦尔贝纳40毫克/天 (VAL40) 之间的16个结局的比较.
- 使用了标准化的平均差异和风险比率,具有95%的置信区间.
主要成果:
- 与安慰剂相比,VAL80和VAL40都显著改善了TD症状 (AIMS得分,CGI-TD,治疗反应).
- 在AIMS得分和治疗反应方面,VAL80表现出比VAL40更高的疗效.
- 在活性治疗和安慰剂之间,或在VAL80和VAL40之间,在可接受性,耐受性或安全性方面没有发现显著差异.
结论:
- 瓦尔贝纳在治疗TD时有效,每天40毫克和每天80毫克.
- 将瓦尔贝纳剂量从每天40毫克增加到每天80毫克可能对那些接受较低剂量的治疗反应不足的患者有益.
- 支持将剂量升级至80毫克/天,以提高TD管理的有效性.
相关概念视频
Parkinson's Disease: Treatment
295
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
295
Antidepressant Drugs: MAOIs and Other Agents
270
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
270
Antipsychotic Drugs: Typical and Atypical Agents
244
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
244
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
339
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
339
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
378
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
378
Antiepileptic Drugs: Potassium Channel Activators
210
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
210


